Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Askelof, P.
  • Rodmalm, K.
  • Wrangsell, G.
  • Larsson, U.
  • Svenson, S. B.
  • Cowell, J. L.
  • Unden, A.
  • Bartfai, Tamas

publication date

  • 1991

journal

  • Developments in Biological Standardization  Journal

abstract

  • Five synthetic peptides identified as antigenic sites on the S1 subunit of pertussis toxin (PT) were coupled to the diphtheria toxin cross-reactive mutant protein CRM 197 or BSA. All peptide conjugates were immunogenic in animals. Two peptide-CRM-conjugates, corresponding to amino acids 1-17 and 169-186, induced especially high antibody titers against native PT in mice (Balb/c, C57/Black and outbred NMRI) as measured by ELISA. Upon in vivo PT challenge (0.5 microgram toxin) of the NMRI mice both the CRM and BSA conjugates of these two peptides fully protected the mice from PT induced leucocytosis. Some of the protected mice receiving peptide 1-17 conjugate had very low antibody titers against PT but high titers against the peptide as measured by ELISA, showing that PT-ELISA does not always reflect in vivo protection. A booster response against PT was noted upon challenge with PT in mice receiving peptide 1-17 or peptide 169-186 conjugate. Antibodies against peptide 170-186 could not be evaluated by ELISA since conjugates of this peptide (like PT itself) bind to immunoglobulins. They may also caused clustering of CHO cells. Rabbit antiserum to the peptide 1-17-CRM conjugate was highly efficient in inhibiting the ADP-ribosylating activity of PT with bovine transducin as substrate whereas the rabbit antiserum raised against the peptide 169-186-CRM conjugate neutralized the clustering effect of PT on CHO cells. Thus there is no concise correlation between the in vivo protection against PT challenge and the in vitro methods used for measuring antibody levels against PT (neutralization of the enzyme activity, the CHO cell clustering activity and titers in PT-ELISA). The CRM-conjugates of these two peptides constitute the first synthetic pertussis vaccine candidate with the ability to provide a chemically well defined, safe and efficient pertussis vaccine.

subject areas

  • Amino Acid Sequence
  • Animals
  • Antibodies, Bacterial
  • Antigens, Bacterial
  • Bacterial Proteins
  • Bordetella pertussis
  • Leukocytosis
  • Mice
  • Mice, Inbred Strains
  • Molecular Sequence Data
  • Peptides
  • Pertussis Toxin
  • Pertussis Vaccine
  • Vaccines, Synthetic
  • Virulence Factors, Bordetella
  • Whooping Cough
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0301-5149 (Print) 0301-5149 (Linking)

PubMed ID

  • 1778305
scroll to property group menus

Additional Document Info

start page

  • 111

end page

  • 120

volume

  • 73

©2019 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support